Animal Model:Neonatal Sprague-Dawley rats (male, 18-22g, postnatal day 7), hypoxic-ischemic brain damage (HIBD) model [2] Dosage:100 mg/kg Administration:Intraperitoneal injection, once daily, for 14 consecutive days starting 24 hours after HIBD induction Result:Brain injury: Reduced infarct volume by 40% compared to the HIBD control group as measured by triphenyltetrazolium chloride (TTC) staining
One NMA comparing GLP-1 agents (dulaglutide, exenatide, efpeglenatide, liraglutide, lixisenatide, semaglutide, and taspoglutide) in terms of change in weight and AEs in adults with obesity or overweight was found 31 and the results for semaglutide versus liraglutide 3.0 mg were consistent with the results for the sponsor-submitted NMA
Evidence for involvement of furin in cleavage and activation of diphtheria toxin
Retatrutide is a triple receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors
By combining your thyroid baseline labs, genetic predisposition data, and clinical history, you and your provider can create a more personalized GLP-1 monitoring plan